Comparative Effectiveness of Therapies for Children With Autism Spectrum Disorders
Note Regarding Possible Harms
Adverse events were not reported for most interventions. They were reported, however, for the antipsychotics risperidone and aripiprazole (see clinical bottom line), serotonin-reuptake inhibitors (decreased sleep, increased energy), guanfacine, and stimulants. Other than for risperidone and aripiprazole, there was not enough evidence to permit conclusions to be drawn about the severity and frequency of potential adverse events associated with any of the interventions. According to the U.S. Food and Drug Administration, there are serious safety issues associated with chelation products. Even when used under medical supervision, these products may cause serious harm, including dehydration, kidney failure, and death.
- Warren Z, Veenstra V-W, Stone W, et al. Therapies for Children With Autism Spectrum Disorders. Comparative Effectiveness Review No. 26 (Prepared by the Vanderbilt University Evidence-based Practice Center under Contract No. 290-2007-10065-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2011. AHRQ Publication No. 11-EHC029-EF.
- U.S. Food and Drug Administration Web site. FDA Consumer Health Information. FDA Warns Marketers of Unapproved ‘Chelation’ Drugs. Available at: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM229436.pdf. Accessed May 17, 2011.
Your slide tray is being processed.